Alexion

Navigating Uncertainty in the Biopharma Market

Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some analysts, while others project a prolonged slump due to inflation and global instability. Established pharmaceutical companies are often seen as safer investments, with larger developers expected to perform well in 2023, especially if litigation threats against drugs like Zantac disappear. However, concerns about revenue gaps continue for big companies like GSK and Sanofi, and their strategy and leadership will be closely monitored in the coming months.

Amgen-Horizon Deal under Intense Scrutiny

Amgen’s proposed acquisition of Horizon Therapeutics for $28.7 billion, including debt, would be the largest healthcare deal since AstraZeneca’s $39 billion purchase of Alexion in 2021, if it goes ahead. As such, it is under intense scrutiny.

Alexion Strengthens Genomics with LogicBio Buy

AstraZeneca’s rare disease arm Alexion has agreed to acquire LogicBio, a US clinical-stage specialist in genomic medicines.

GSK Names Julie Brown as First Female CFO

From next year, GSK’s top management will be led by a double female team, a pioneering move for the global pharmaceutical industry. The UK drugs giant this week announced the appointment of Julie Brown, the first woman to be its chief financial officer.

EU Approves AstraZeneca Takeover of Alexion

EU competition authorities have approved AstraZeneca’s $39 billion takeover of US biopharma Alexion. Europe’s green light for the deal sealed in December 2020 follows the approval of the US Federal Trade Commission (FTC) in April 2021.

UK Regulator Casts Doubt on AstraZeneca’s Alexion Buy

AstraZeneca’s agreement to acquire Alexion Pharma for $39 billion, sealed in December 2020 and approved by the US Federal Trade Commission (FTC) in April 2021, may not be a done deal after all. The UK’s Competition and Markets Authority (CMA) announced on May 25 that it has launched an anti-competition investigation into the transaction.

Alexion to Buy Wilson Therapeutics for $855 Million

Lonza Signs New Agreement with Alexion

Alexion Recalls Certain Lots of Intravenous Drug Soliris

Alexion Valuation Could Choke Any Roche Bid

Top-Selling Drugs for Ultra-Rare Diseases

Entering the Age of the $1 Million Medicine

Surge in Biotech Deals to Unlock Big Investor Profits

Major Drugmakers Looking to Purchase Smaller Companies